Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
The relationship between statin-induced increases in HDL cholesterol (HDL-C) concentration and statin-induced decreases in LDL cholesterol (LDL-C) is unknown. The effects of different statins on HDL-C levels, relationships between changes in HDL-C and changes in LDL-C, and predictors of statin-induced increases in HDL-C have been investigated in an individual patient meta-analysis of 32,258 dyslipidemic patients included in 37 randomized studies using rosuvastatin, atorvastatin, and simvastatin. The HDL-C raising ability of rosuvastatin, and simvastatin was comparable, with both being superior to atorvastatin. Increases in HDL-C were positively related to statin dose with rosuvastatin and simvastatin but inversely related to dose with atorvastatin. There was no apparent relationship between reduction in LDL-C and increase in HDL-C, whether analyzed overall for all statins (correlation coefficient = 0.005) or for each statin individually. Percentage increase in apolipoprotein A-I was virtually identical to that of HDL-C at all doses of the three statins. Baseline concentrations of HDL-C and triglyceride (TG) and presence of diabetes were strong, independent predictors of statin-induced elevations of HDL-C. Statins vary in their HDL-C raising ability. The HDL-C increase achieved by all three statins was independent of LDL-C decrease. However, baseline HDL-C and TGs and the presence of diabetes were predictors of statin-induced increases in HDL-C.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Statins also elevate high-density lipoprotein cholesterol (HDL-C) in a dose-dependent manner by up to + 10% [32].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [32]
In the citing paper
“Moreover, the long-term safety of the regular consumption of these products has not been fully documented and safety issues due to the possible presence of contaminants in some preparations have been raised.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [185]
In the citing paper
“Different commercial preparations of RYR have different concentrations of monacolins, and lower TC and LDL-C levels to variable extents, but the consumer is not able to make that distinction [144,185].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [185]
In the citing paper
“Hypocholesterolaemic effects of RYR are related to a statin-like mechanism-inhibition of hydroxymethylglutaryl-coenzyme A (HMGCoA) reductase-of monacolins, which represent the bioactive ingredient.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [185]
In the citing paper
“In a meta-analysis 291 of several intervention studies in dyslipidaemic patients, elevations in HDL-C varied with dose among the respective statins; such elevations were typically in the range of 5-10%.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [291]
Citations
Cites
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Jones, P. H., Davidson, M. H., Stein, E. A., Bays, H. E., McKenney, J. M., Miller, E., Cain, V. A., & Blasetto, J. W. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00530-7 · Cited by 1,398
Diabetes and atherosclerosis: An epidemiologic view
Pyörälä, K., Laakso, M., & Uusitupa, M. (1987) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610030206 · Cited by 919
Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis
Nicholls, S. J., Tuzcu, E. M., Sipahi, I., Grasso, A. W., Schoenhagen, P., Hu, T., Wolski, K., Crowe, T., Desai, M. Y., Hazen, S. L., et al. (2007) · JAMA · doi:10.1001/jama.297.5.499 · Cited by 724
Self-citationPedersen, T. R., Olsson, A. G., Færgeman, O., Kjekshus, J., Wedel, H., Berg, K., Wilhelmsen, L., Haghfelt, T., Thorgeirsson, G., Pyörälä, K., et al. (1998) · Circulation · doi:10.1161/01.cir.97.15.1453 · Cited by 621
Rubins, H. B. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.22.2597 · Cited by 586
Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia
Davidson, M. H., McGarry, T., Bettis, R., Melani, L., Lipka, L. J., LeBeaut, A. P., Suresh, R., Sun, S., & Veltri, E. P. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02610-4 · Cited by 558
Cited by
Items 101–200 of 260
Chapman, M. J., Orsoni, A., Robillard, P., Thérond, P., & Giral, P. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.02.001 · Cited by 20
Christiansen, C., Jeppesen, P. B., Hermansen, K., & Gregersen, S. (2023) · Nutrients · doi:10.3390/nu15245094 · Cited by 17
Familial Aggregation of Metabolic Syndrome Indicators in Portuguese Families
Santos, D., Katzmarzyk, P. T., Trégouët, D., Gomes, T. N., dos Santos, F. K., & Maia, J. A. R. (2013) · BioMed Research International · doi:10.1155/2013/314823 · Cited by 18
Wang, Q., Guo, L., Strawser, C. J., Hauser, L. A., Hwang, W., Snyder, N. W., Lynch, D. R., Mesaros, C., & Blair, I. A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192779 · Cited by 18
Karlson, B. W., Barter, P. J., Palmer, M. K., Lundman, P., & Nicholls, S. J. (2012) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2012.03.003 · Cited by 16
Self-citationTargeting High-Density Lipoproteins: Increasing De Novo Production Versus Decreasing Clearance
Mooradian, A. D., & Haas, M. J. (2015) · Drugs · doi:10.1007/s40265-015-0390-1 · Cited by 17
“Other agents that have only modest effects on HDLc, such as the statins [41, 42] and thiazolidinediones [43, 44], have more robust effects on lipids or carbohydrate metabolism which would obscure the relative contribution of the changes in HDLc to the clinical outcomes.”
BackgroundTakagi, H., & Umemoto, T. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.08.043 · Cited by 18
Beaney, K. E., Cooper, J. A., McLachlan, S., Wannamethee, S. G., Jefferis, B. J. M. H., Whincup, P. H., Ben‐Shlomo, Y., Price, J. F., Kumari, M., Wong, A., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0435-0 · Cited by 13
“For example, rosuvastatin and simvastatin have been found to have a much greater HDL-cholesterol raising ability compared to atorvastatin [33].”
BackgroundHu, M., Mak, V. W. L., & Tomlinson, B. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.02.005 · Cited by 19
Pedrini, S., Hone, E., Gupta, V. B., JAMES, I. R., Teimouri, E., Bush, A. I., Rowe, C. C., Villemagne, V. L., Ames, D. J., Masters, C. L., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200291 · Cited by 18
Emerging options in the treatment of dyslipidemias: a bright future?
Florentin, M., Liberopoulos, E. N., Mikhailidis, D. P., & Elisaf, M. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.554395 · Cited by 14
“In contrast, atorvastatin, a widely used statin, does not raise HDL-C as much as other statins especially at high doses [44].”
BackgroundPedoman Tatalaksana Dislipidemia PERKI 2013
Erwinanto, E., Santoso, A., Putranto, J. N., Tedjasukmana, P., Suryawan, R., Rifqi, S., & Kasiman, S. (2015) · Indonesian Journal of Cardiology · doi:10.30701/ijc.v34i4.385 · Cited by 18
Huang, C., Chen, W., Shia, B., Chen, M., & Wu, S. (2023) · Head & Neck · doi:10.1002/hed.27358 · Cited by 15
Bener, A., Dogan, M., Barakat, L., & Al-Hamaq, A. O. A. A. (2014) · Journal of Primary Care & Community Health · doi:10.1177/2150131914520991 · Cited by 13
“And finally, it has been found that baseline concentrations of HDL-C and plasma TG and the presence of diabetes are robust, independent predictors of statin-induced elevations of HDL-C.11,14 More recently, various studies7,18 reported that patients with MetS had greater reductions in TG and somewhat greater percentage…”
ResultTakagi, H., Niwa, M., Mizuno, Y., Yamamoto, H., Goto, S.-N., & Umemoto, T. (2013) · Heart and Vessels · doi:10.1007/s00380-013-0358-6 · Cited by 13
“Another analysis [50] of the VOYAGER database has revealed that the HDL-raising ability of rosuvastatin and simvastatin was comparable, with both being superior to atorvastatin.”
BackgroundHDL metabolism and function in diabetes mellitus
Cochran, B. J., King, T. W., Chemello, K., Thomas, S. R., & Rye, K. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01176-y · Cited by 18
“A large meta-analysis has reported that treatment with rosuvastatin, atorvastatin or simvastatin increases HDL cholesterol by 4.2% to 7.9% and increases APOA1 by 0.1% to 6.5% in patients with dyslipidaemia, independent of LDL cholesterol lowering 143 .”
InfluentialWong, T. L., Kong, Y., & Ma, S. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000837 · Cited by 19
“[195] The development of a suitable preclinical model to recapture the inter-patient difference observed in patients is crucial.”
Arshad, A. R. (2014) · Journal of Lipids · doi:10.1155/2014/875907 · Cited by 12
Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia
Benes, L. B., Bassi, N. S., & Davidson, M. H. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s58149 · Cited by 13
Liu, N., Yang, G., Hu, M. L., Cai, Y., Hu, Z., Jia, C., & Zhang, M. (2018) · Pharmacogenomics · doi:10.2217/pgs-2018-0084 · Cited by 14
Ota, T., Ishii, H., Suzuki, S., Tanaka, A., Shibata, Y., Tatami, Y., Harata, S., Shimbo, Y., Takayama, Y., Kawamura, Y., et al. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.11.043 · Cited by 11
High-Density Lipoproteins and Acute Kidney Injury
Smith, L. E. (2020) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2020.01.013 · Cited by 14
Kyhl, L. K., Nordestgaard, B. G., Tybjærg‐Hansen, A., & Nielsen, S. F. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120551 · Cited by 16
Optimal statin use for prevention of sepsis in type 2 diabetes mellitus
Sun, M., Tao, Y., Chen, W., Wu, S., & Zhang, J. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01041-w · Cited by 10
“The effects of statins on LDL, HDL, and triglycerides might differ on the basis of their intensity and daily dose because we observed a U-shaped dose–response relationship for the effect of the daily dose of statins on LDL, HDL, and triglycerides [41, 44].”
BackgroundMayer, O., Bruthans, J., Seidlerová, J., Karnosová, P., Vaněk, J., Hronová, M., Gelžinský, J., Cvíčela, M., Wohlfahrt, P., Cífková, R., et al. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.07.018 · Cited by 10
Li, Z., Zhu, Q., Azad, M. A. K., Li, H., Huang, P., & Kong, X. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.778555 · Cited by 10
Ramachandran, S., Abbas, A., Saraf, S., Raju, J., Jewkes, C., & Jones, A. F. (2012) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2011.0112 · Cited by 10
“Although simvastatin, rosuvastatin, and atorvastatin all increased HDL-C, the dose–response effect of atorvastatin on HDL-C change was inverse.(26) However, none of these findings offer an explanation for our observation of insignificant HDL-C change in patients on statins.”
The beneficial effects of HDL-C on atherosclerosis: rationale and clinical results
Santos‐Gallego, C. G., Torres, F., & Badimón, J. J. (2011) · Clinical Lipidology · doi:10.2217/clp.10.90 · Cited by 11
Yun, K. H., Shin, S.-N., Ko, J. S., Rhee, S. J., Kim, N., Oh, S. K., & Jeong, J. (2012) · Journal of Cardiology · doi:10.1016/j.jjcc.2012.07.008 · Cited by 11
Bramlage, P., Lanzinger, S., Rathmann, W., Gillessen, A., Scheper, N., Schmid, S. M., Kaltheuner, M., Seufert, J., Danne, T., & Holl, R. W. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12783 · Cited by 11
Lipid-lowering drugs, dyslipidemia, and breast cancer risk in a Medicare population
Schairer, C., Freedman, D. M., Gadalla, S. M., & Pfeiffer, R. M. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4680-7 · Cited by 14
Very low HDL levels: clinical assessment and management
Bonilha, I., Luchiari, B., Nadruz, W., & Sposito, A. C. (2023) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000585 · Cited by 20
“Furthermore, the percentage increases in HDL-C levels were greater in those individuals who had lower baseline plasma HDL-C levels (78).”
BackgroundChu, A. Y., Giulianini, F., Barratt, B. J., Ding, B., Nyberg, F., Mora, S., Ridker, P. M., & Chasman, D. I. (2015) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.114.000962 · Cited by 11
“such as HDL-C.(13) To fully explore alternate pathways influ-”
BackgroundInfluentialWaluś‐Miarka, M., Czarnecka, D., Kloch‐Badełek, M., Wojciechowska, W., Kapusta, M., & Malecki, M. T. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.06.076 · Cited by 11
Mohammadi, F., Yadegar, A., Rabizadeh, S., Ayati, A., Seyedi, S. A., Nabipoorashrafi, S. A., Esteghamati, A., & Nakhjavani, M. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02010-6 · Cited by 16
“The impact of statins on HDL-C is controversial; analyses of data have added support to the proposition that statins may correspond to only a 5–10% increase or no changes in HDL-C levels [7, 12, 13].”
BackgroundSanto, V., Brunetti, L., Pecci, F., Peroni, M., Barnini, G., Paoloni, F., Buti, S., Tiseo, M., Ricciuti, B., Pinato, D. J., et al. (2025) · Current Oncology Reports · doi:10.1007/s11912-025-01718-7 · Cited by 15
“Moreover, statins help reduce systemic inflammation and improve cardiovascular health, ultimately benefiting overall patient well-being [ 93, 94 ].”
Pecci, F., Cognigni, V., Giudice, G. C., Paoloni, F., Cantini, L., Saini, K. S., Abushukair, H. M., Naqash, A. R., Cortellini, A., Mazzaschi, G., et al. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104654 · Cited by 11
Lau, K. K., Tancredi, D. J., Perez, R. V., & Butani, L. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.08431109 · Cited by 9
Zhang, Y., Luo, S., Gao, Y. Q., Tong, W., & Sun, S. (2023) · Angiology · doi:10.1177/00033197231157473 · Cited by 9
“81 For example, the response of atorvastatin to elevated HDL-C appeared to decline with increasing dose, by contrast, rosuvastatin showed a more consistent dose-response relationship in terms of both LDL-C reduction and HDL-C elevation.”
BackgroundAmadid, H., Rønn, P. F., Dunbar, M. B., Knudsen, J. S., Carstensen, B., Persson, F., & Jørgensen, M. E. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14478 · Cited by 8
Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies
Aslibekyan, S. W., Straka, R. J., Irvin, M. R., Claas, S. A., & Arnett, D. K. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.134 · Cited by 8
Nicholls, S. J., Uno, K., & Kataoka, Y. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.145 · Cited by 11
Self-citationLiu, Y., Chen, J., Yuan, Y., Niu, P., Wu, M., Shang, B., Lu, W., Zou, X., & Yao, G. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1520107 · Cited by 7
de Medrano, J. I. S., & Brunet, M. (2023) · Advances in Laboratory Medicine / Avances en Medicina de Laboratorio · doi:10.1515/almed-2023-0123 · Cited by 17
“In addition, depending on the dose and type of statin, these drugs cause a 1 – 10 % increase in levels of high density lipoproteins (HDL) [20].”
BackgroundDyslipidemia: Current Therapies and Strategies to Overcome Barriers for Use
DePhillips, C., Parikh, P. B., & Stevens, G. (2021) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2021.08.012 · Cited by 8
Rašković, A., Martić, N., Tomás, A., Andrejić-Višnjić, B., Bosanac, M., Atanasković, M., Nemet, M., Popović, R., Krstić, M., Vukmirović, S., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15112611 · Cited by 8
Sun, M., Chen, W., Wu, S., & Zhang, J. (2023) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2023.11.010 · Cited by 7
Zhou, X., Wu, L., Chen, Y., Xiao, H., Huang, X., Li, Y., Xiao, H., & Cao, X. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13472 · Cited by 7
Li, Y., Tseng, W., Yin, W., Lin, F., Wu, Y., Hsieh, C., Lin, T., Sheu, W. H., Yeh, H., Chen, J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-78828-8 · Cited by 8
Katabami, T., Murakami, M., Kobayashi, S., Matsui, T., Ujihara, M., Takagi, S., Higa, M., Ichijo, T., Ohta, A., & Tanaka, Y. (2014) · Journal of International Medical Research · doi:10.1177/0300060513507648 · Cited by 7
Ramachandran, S., Saraf, S., Shetty, C. S. C., Capps, N. E., & Bailey, C. J. (2010) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/acb.2010.010081 · Cited by 7
Yang, K., Chen, H., Chuang, C., Chiang, Y.-C., & Lin, L.-Y. (2025) · Journal of Oleo Science · doi:10.5650/jos.ess24171 · Cited by 7
Yu, J.-M., Chen, W., Chen, M., Shia, B.-C., & Wu, S. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03488-2 · Cited by 6
Targeting NPC1 in Renal Cell Carcinoma
Fazliyeva, R., Makhov, P. B., Uzzo, R. G., & Kolenko, V. M. (2024) · Cancers · doi:10.3390/cancers16030517 · Cited by 8
“However, these drugs up-regulate HDL levels [60,65–68], which can serve as a source of cholesterol for tumor cells.”
BackgroundAssociation between HbA1c and dyslipidemia among sample of Iraqi Patients with Type2 DM
Hami, A. M. (2021) · Journal of the Faculty of Medicine Baghdad · doi:10.32007/jfacmedbagdad.6331864 · Cited by 10
Kwon, S. J., Hong, K., Choi, S., Hong, J. S., Kim, J. W., Kim, J. W., Lee, H., Jang, H. B., & Yum, K. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00877-3 · Cited by 9
“As previously stated, statins reduce LDL cholesterol and triglyceride levels and increase high density lipoprotein cholesterol level by inhibiting HMGCR activity (Barter et al. 2010; Karlson et al. 2016).”
BackgroundYu, J.-M., Chen, W., Chen, M., Shia, B., & Wu, S. (2023) · Pharmaceuticals · doi:10.3390/ph16040507 · Cited by 7
“At maximal prescribed doses, rosuvastatin provides a greater LDL reduction than other statins [33,34].”
BackgroundResultInfluentialDifferential effect of metabolic syndrome on various parameters of arterial stiffness
Vágovičová, P., Seidlerová, J., Mayer, O., Wohlfahrt, P., Cífková, R., & Filipovský, J. (2015) · Blood Pressure · doi:10.3109/08037051.2015.1049420 · Cited by 6
Jin, X., Zeng, F., Zhang, N., Huang, T., Meng, Q., & Liu, Y. (2012) · Journal of International Medical Research · doi:10.1177/147323001204000116 · Cited by 6
Hu, M., Yang, Y., Ng, C., Lee, C. P., Lee, V. W. Y., Hanada, H., Masuda, D., Yamashita, S., & Tomlinson, B. (2015) · Medicine · doi:10.1097/md.0000000000000881 · Cited by 6
“This is consistent with the published data from large randomized clinical trials with ER niacin.39,40 In the AIM-HIGH trial, the addition of ER niacin to simvastatin therapy during a 3-year mean follow-up period was associated with a 25% increase in HDL-C, but was only associated with a 4.1% increase in apoAI.39 Howev…”
ResultInfluentialFerrières, J., Lautsch, D., Bramlage, P., Horack, M., Baxter, C. A., Ambegaonkar, B. M., Toth, P. P., Poh, K. K., Ferrari, G. M. D., & Gitt, A. K. (2020) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2020.05.013 · Cited by 7
Therapeutics in Metabolic Diseases
Natesan, V. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-5642-3_17 · Cited by 5
High-Throughput Analysis Identifying Drugs That Regulate Apolipoprotein A-I Synthesis
Haas, M. J., Onstead‐Haas, L., Kurban, W., Shah, H., Plazarte, M., Chamseddin, A., & Mooradian, A. D. (2017) · Assay and Drug Development Technologies · doi:10.1089/adt.2017.782 · Cited by 6
“1 The currently available agents that increase HDL production through increased apo A-I gene transcription include fibrates, 6 statins, 7 and pioglitazone.”
Statin-treated RBC dynamics in a microfluidic porous-like network
Stathoulopoulos, A., König, C. S., Ramachandran, S., & Balabani, S. (2024) · Microvascular Research · doi:10.1016/j.mvr.2024.104765 · Cited by 5
HDL–Cholesterol: Perfection is the Enemy of Good?
Baliga, R. R. (2012) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.01.001 · Cited by 5
“dependent increase in HDL-C with both rosuvastatin and simvastatin, whereas, for atorvastatin, the increase in HDL-C was inversely related to dose.(22) There was no relationship between statin-induced changes in HDL-C and changes in LDL-C.”
BackgroundKashyap, S. R., Kheniser, K. G., Li, L., Bena, J., & Kasumov, T. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0314-4 · Cited by 5
“However, it is plausible that apoA-1 levels increased, given that HDL levels improved after 12 months of IMT [44].”
Discovery and Exploration of Lipid-Modifying Drug Targets for ALS by Mendelian Randomization
Jiang, Z., Gu, X., Su, W., Duan, Q., Yin, K., Ren, Y., Wang, Y., Cao, B., & Chen, Y. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04007-9 · Cited by 5
“For example, although reducing LDL and TC levels is the major effect of statins ( HMGCR ), modifying effects on TG [31], HDL [32], ApoB [33], and ApoA1 [32] have also been suggested.”
Nezhadebrahimi, A., Sepehri, H., Jahanshahi, M., Marjani, M., & Marjani, A. (2020) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2020.1772829 · Cited by 5
“A study on LDLR-deficient mice has also revealed that LDLR deficiency may prevent the accumulation of cholesterol and b cell dysfunction in pancreatic b cells (Barter et al. 2010).”
BackgroundTLR4 modulates simvastatin’s impact on HDL cholesterol and glycemic control
Tian, X., & Zhang, P. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1655873 · Cited by 6
Lawton, R. I., Frankenberg, E., Seeman, T. E., Karlamangla, A. S., Sumantri, C. S., & Thomas, D. (2024) · Economics & Human Biology · doi:10.1016/j.ehb.2024.101403 · Cited by 5
“Third, while statin drugs can have dramatic impacts on non-HDL cholesterol levels, their effects on HDL cholesterol are very small, potentially increasing levels slightly (Barter et al., 2010).”
BackgroundNonenzymatic Mechanism of Statins in Modulating Cholesterol Particles Formation
Madasamy, S., Shivasubramani, U., Villanueva, J., Bigos, M., Amento, E. P., & Wu, A. H. B. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.07.035 · Cited by 3
Kim, J., Kim, H.-S., Bae, Y.-J., Lee, H.-C., Lee, J., & Kang, H. (2021) · PLoS ONE · doi:10.1371/journal.pone.0247419 · Cited by 4
Pio-Magalhães, J. A., Ferreira-Sae, M. C., Souza, F. A. S., Grespan-Magossi, A. M., Schreiber, R., Velloso, L. A., Geloneze, B., Franchini, K. G., & Nadruz, W. (2011) · PubMed · doi:10.3275/7725 · Cited by 4
Gangappa, K., Rao, U. J. S. P., Salimath, P. V., & Chilkunda, N. D. (2017) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-017-0583-z · Cited by 5
Optimizing statin therapy in HIV-infected patients: a review of pharmacotherapy considerations
Ansari, R., Khalili, H., & Mohammadi, K. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-04887-2 · Cited by 4
“Variations exist in the effect of statins on HDL levels, both as the type of the effect (increase/decrease) and dose rel-evancy, mainly due to their different effects on hepatic microRNA33 [25].”
Yu, J.-M., Chen, W., Shia, B., & Wu, S. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01135-w · Cited by 3
The Role of Statins in Prevention of Cardiovascular Diseases in Real Clinical Practice
IuA, K., & Moscow, R. F. (2021) · Doctor Ru · doi:10.31550/1727-2378-2021-20-11-17-27 · Cited by 4
Lipid-lowering Eeficacy and Safety of High Doses of Atorvastatin and Rosuvastatin
Susekov, A. V. (2023) · Kardiologiia · doi:10.18087/cardio.2023.2.n2407 · Cited by 4
Kudinov, V. A., Zakharova, T. S., Torkhovskaya, T. I., Ipatova, O. M., & Archakov, A. I. (2018) · Biochemistry (Moscow) Supplement Series B Biomedical Chemistry · doi:10.1134/s1990750818020075 · Cited by 3
Roumeliotis, S. K., Liakopoulos, V., Roumeliotis, A. K., Stamou, A. C., Panagoutsos, S. A., D’Arrigo, G., & Tripepi, G. L. (2021) · International Urology and Nephrology · doi:10.1007/s11255-021-02828-4 · Cited by 3
“The HDL cholesterol response to any given statin might vary widely among studies, with little understanding of the factors that may be responsible for such variation [44].”
BackgroundIriani, Y., Ramona, Y., & Astiti, N. P. A. (2021) · Metamorfosa Journal of Biological Sciences · doi:10.24843/metamorfosa.2021.v08.i01.p09 · Cited by 3
Raising high-density lipoprotein: for better or worse?
Tomlinson, B. (2010) · Heart · doi:10.1136/hrt.2010.202788 · Cited by 2
“Increases in HDL-cholesterol are positively related to statin dose with rosuvastatin and simvastatin but inverselywith atorvastatin, so the change in HDL-cholesterol in statin studies will vary with the drug, the dose and the study population.(13) The increase in non-cardiovascular death in ILLUMINATE was from cancer…”
BackgroundInfluentialBouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2026) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2026.01.001 · Cited by 2
Murlasits, Z. (2015) · The Physician and Sportsmedicine · doi:10.1080/00913847.2015.1095618 · Cited by 3
Is it Time to Enhance Assessment of Alcohol Intake in Patients Slated for Statin Therapy?
Kabagambe, E. K., & Fazio, S. (2014) · Current Nutrition Reports · doi:10.1007/s13668-014-0107-1 · Cited by 2
Toms, R., Mayne, D. J., Feng, X., & Bonney, A. D. (2020) · Scientific Reports · doi:10.1038/s41598-020-69552-4 · Cited by 2
de Medrano, J. I. S., & Brunet, M. (2023) · Advances in Laboratory Medicine / Avances en Medicina de Laboratorio · doi:10.1515/almed-2023-0064 · Cited by 9
“…deberse a una mayor captación del colesterol con lipoproteínas de muy baja densidad (VLDL) en los hepatocitos, así como a una disminución en la producción de VLDL. Además, dependiendo de la dosis y de la estatina, aumentan el coles-terol con lipoproteínas de alta densidad (HDL) entre 1 – 10 % [20].”
BackgroundTherapeutic approach in the treatment of dyslipidemia: Novelties and challenges
Lalic, K. S., Rajkovic, N., Popović, L., Lukač, S. S., Rasulić, I., Petakov, A., Krstic, M., & Mitrović, M. (2024) · Galenika Medical Journal · doi:10.5937/galmed2409031l · Cited by 2
Statin therapy improves outcomes in infective endocarditis: evidence from a meta-analysis
Yaghoobi, M. H., Heidari, E., Shafiee, A., Seighali, N., Maghsoodi, M. R., & Bakhtiyari, M. (2024) · The Egyptian Heart Journal · doi:10.1186/s43044-024-00495-1 · Cited by 2
“…effects of statin, the ratio for possible effect of using statins for therapeutic purposes in IE patients may lie behind its potential impact in increasing high-density lipoprotein (HDL-C) levels, which has reported to be decreased in patients with severe infectious diseases [15–17].”
BackgroundShuja, D., Mian, M. U., Dhanjal, M. K., Mengar, J., Butt, A. A., Chaudhari, S. S., Wei, C. R., & Khan, A. A. (2024) · Cureus · doi:10.7759/cureus.68602 · Cited by 4
“Clinical studies suggest that rosuvastatin may offer superior LDL-C lowering capabilities, but atorvastatin remains a highly effective and widely used option in lipid management [8].”
BackgroundDynamics of HDL-Cholesterol Following a Post-Myocardial Infarction Cardiac Rehabilitation Program
Bertolín‐Boronat, C., Merenciano-Gonzalez, H., Marcos‐Garcés, V., Mas, M. L. M., Alberola, J. I. C., Pérez-Solé, N., López, L., Argente, M. C. E., Reig, M. V., Benito, A. A., et al. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm25399 · Cited by 3
Xu, S., Yang, Y. R., Liu, H., Yang, Y., Li, X., Du, Y., & Lu, N. (2025) · Pharmacology · doi:10.1159/000547674 · Cited by 2
“This dual action is clinically significant, as low HDL-C is a persistent risk factor for CVD, even in patients with well-controlled LDL-C [17, 18].”
Lipid modifying action of atorvastatin in escalating doses in patients of coronary artery disease
Paul, S., Mondal, S., Mondal, H., & Hossain, S. (2014) · International Journal of Basic & Clinical Pharmacology · doi:10.5455/2319-2003.ijbcp20140819 · Cited by 2
Chang, Y., Lin, K., Shin, S., & Lee, Y. J. (2014) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2014.04.010 · Cited by 2
Mayer, O., Seidlerová, J., Bruthans, J., Timoracká, K., Vágovičová, P., Vaněk, J., Wohlfahrt, P., Filipovský, J., & Cífková, R. (2014) · Clinical Lipidology · doi:10.2217/clp.14.49 · Cited by 2
Geamanu, A., Goja, A., Saadat, N., Khosla, P., & Gupta, S. V. (2013) · Nutrition & Metabolism · doi:10.1186/1743-7075-10-55 · Cited by 2
“from the effect of a high fat diet on lipid profiles, a number of recent metabolomic studies have identified abnormalities in branched chain amino acids [29], choline, betaine, and trimethylamine N-oxide (TMAO) metabolism as being highly increased in subjects with atherosclerosis, heart failure, and other cardiovascul…”
BackgroundKong, J. P., Ayub, A. B., & Bau, R. A. (2016) · Nutrition & Food Science · doi:10.1108/nfs-09-2015-0115 · Cited by 2
Strategies for the use of nonstatin therapies
Pirillo, A., Norata, G. D., & Catapano, A. L. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000459 · Cited by 2
ROSUVASTATIN - THE MOST POTENT STATIN IN CARDIOVASCULAR DISEASE PREVENTION
Семенова, А. Е., & Сергиенко, И. В. (2018) · Eurasian heart journal · doi:10.38109/2225-1685-2018-2-28-41 · Cited by 2
Bouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2026) · Diabetes & Metabolism · doi:10.1016/j.diabet.2026.101725 · Cited by 3
Metadata
- Authors
- Barter, P. J., Brandrup-Wognsen, G., Palmer, M. K., & Nicholls, S. J.
- Affiliations
- The Heart Research Institute (AU)
- Keele University (GB)
- Cleveland Clinic (US)
- Corresponding author
- Barter, Philip J.
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2010-06
- Volume
- 51
- Issue
- 6
- Pages
- 1546-1553
- ISSN
- 0022-2275 (ISSN-L)
- PMC
- PMC3035518
- OpenAlex
- W2134105637
- Cited by
- 259
- References
- 38
- Citations by year
- 2026: 12 · 2025: 18 · 2024: 16 · 2023: 23 · 2022: 11 · 2021: 19 · 2020: 17 · 2019: 8 · 2018: 16 · 2017: 11 · 2016: 15 · 2015: 15 · 2014: 23 · 2013: 15 · 2012: 13
- FWCI
- 13.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 3790 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- statins, HDL cholesterol, LDL cholesterol, rosuvastatin, atorvastatin, simvastatin, apolipoprotein A-I, triglycerides, diabetes mellitus, dyslipidemia, statin dose
- MeSH terms
- Adolescent, Adult, Aged, Dose-Response Relationship, Drug, Female, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Triglycerides, Randomized Controlled Trials as Topic, Databases, Factual, Apolipoprotein A-I, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.